ClinicalTrialsFinder

HER2-Negative Breast Carcinoma Clinical Trials in Washington D.C., District of Columbia

1 recruitingWashington D.C., District of Columbia

Showing 1–1 of 1 trials

Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377